Victory Capital Management
RUBY

Victory Capital Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Victory Capital Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,932,248
Closed -$16.2M – 2770
2022
Q1 		$16.2M Buy
2,932,248
+489,248
+20% +$3.11M 0.02% 964
2021
Q4 		$23.6M Buy
2,443,000
+631,892
+35% +$8.76M 0.02% 857
2021
Q3 		$32.4M Buy
1,811,108
+238,921
+15% +$5.2M 0.03% 702
2021
Q2 		$38.4M Buy
1,572,187
+371,370
+31% +$9.29M 0.04% 661
2021
Q1 		$31.8M Buy
+1,200,817
New +$17.5M 0.03% 737
2020
Q2 		– Sell
-3,041
Closed -$14K – 3509
2020
Q1 		$14K Buy
+3,041
New +$22.6K ﹤0.01% 2980
2019
Q4 		– Sell
-4,606
Closed -$36K – 3495
2019
Q3 		$36K Buy
+4,606
New +$53.7K ﹤0.01% 2828

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $293M AUM 36.12% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Victory Capital Management's RUBY Position: Q2 2022 in Review

Victory Capital Management sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 2,932,248 shares — an estimated $16.2M sold.

Victory Capital Management first reported a position in RUBY in Q3 2019 and held it in 7 quarters. The position peaked at $38.4M in Q2 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

  • Victory Capital Management reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
  • Victory Capital Management sold 2,932,248 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $16.2M.
  • Victory Capital Management first reported a position in Rubius Therapeutics, Inc in Q3 2019 and held it in 7 quarters.
  • Victory Capital Management's Rubius Therapeutics, Inc position peaked at $38.4M in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Victory Capital Management's 13F filing for Q2 2022, filed 1 Aug 2022.